Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. / Lamberts, Morten; Fosbøl, Emil L; Olsen, Anne-Marie S; Hansen, Morten L; Folke, Fredrik; Kristensen, Søren L; Olesen, Jonas B; Hansen, Peter R; Køber, Lars; Torp-Pedersen, Christian; Gislason, Gunnar H.

In: International Journal of Cardiology, 2013.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lamberts, M, Fosbøl, EL, Olsen, A-MS, Hansen, ML, Folke, F, Kristensen, SL, Olesen, JB, Hansen, PR, Køber, L, Torp-Pedersen, C & Gislason, GH 2013, 'Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction', International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2012.10.004

APA

Lamberts, M., Fosbøl, E. L., Olsen, A-M. S., Hansen, M. L., Folke, F., Kristensen, S. L., Olesen, J. B., Hansen, P. R., Køber, L., Torp-Pedersen, C., & Gislason, G. H. (2013). Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2012.10.004

Vancouver

Lamberts M, Fosbøl EL, Olsen A-MS, Hansen ML, Folke F, Kristensen SL et al. Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. International Journal of Cardiology. 2013. https://doi.org/10.1016/j.ijcard.2012.10.004

Author

Lamberts, Morten ; Fosbøl, Emil L ; Olsen, Anne-Marie S ; Hansen, Morten L ; Folke, Fredrik ; Kristensen, Søren L ; Olesen, Jonas B ; Hansen, Peter R ; Køber, Lars ; Torp-Pedersen, Christian ; Gislason, Gunnar H. / Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. In: International Journal of Cardiology. 2013.

Bibtex

@article{e95a5900932441a8917b2b5a599fcef5,
title = "Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction",
abstract = "BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with increased cardiovascular morbidity and mortality. The purpose of this study was to examine the effect of ongoing NSAID treatment at time of admission for myocardial infarction (MI) on prognosis. METHODS: All patients admitted with first-time MI in 1997-2006 were included by use of individual-level linkage of nationwide registries. By claimed prescription of NSAIDs, availability of tablets was estimated within 14days prior to inclusion and defined ongoing use. Risk of death within 30days and risk of death or MI within 1year was analyzed by logistic regression and Cox proportional-hazard models, respectively. RESULTS: A total of 97,458 patients were included (mean age 69.9 [SD 13.2] years and 62% males); the 30day and 1year mortality rates were 18.1% and 27.7%, respectively. Ongoing NSAID treatment was identified in 12,156 (12.5%) patients and 30-day mortality was significantly increased in patients receiving rofecoxib (odds ratio [OR] 1.43; 95% confidence interval [CI] 1.22-1.68) and celecoxib (OR 1.23; CI 1.03-1.47) relative to no use of NSAIDs. Correspondingly, the 1-year rate of death or recurrent MI was significantly increased in patients receiving rofecoxib (hazard ratio [HR] 1.15; CI 1.04-1.27), celecoxib (HR 1.13; CI 1.01-1.26), diclofenac (HR 1.12; CI 1.04-1.20) or any NSAID use (HR 1.05; CI 1.02-1.09). No association was found for naproxen or ibuprofen. CONCLUSION: Ongoing treatment with NSAIDs and in particular the cyclooxygenase-2-selective inhibitors rofecoxib, celecoxib, and diclofenac is associated with worsened prognosis in patients admitted with first-time MI.",
author = "Morten Lamberts and Fosb{\o}l, {Emil L} and Olsen, {Anne-Marie S} and Hansen, {Morten L} and Fredrik Folke and Kristensen, {S{\o}ren L} and Olesen, {Jonas B} and Hansen, {Peter R} and Lars K{\o}ber and Christian Torp-Pedersen and Gislason, {Gunnar H}",
note = "Copyright {\textcopyright} 2012 Elsevier Ireland Ltd. All rights reserved.",
year = "2013",
doi = "10.1016/j.ijcard.2012.10.004",
language = "English",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction

AU - Lamberts, Morten

AU - Fosbøl, Emil L

AU - Olsen, Anne-Marie S

AU - Hansen, Morten L

AU - Folke, Fredrik

AU - Kristensen, Søren L

AU - Olesen, Jonas B

AU - Hansen, Peter R

AU - Køber, Lars

AU - Torp-Pedersen, Christian

AU - Gislason, Gunnar H

N1 - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

PY - 2013

Y1 - 2013

N2 - BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with increased cardiovascular morbidity and mortality. The purpose of this study was to examine the effect of ongoing NSAID treatment at time of admission for myocardial infarction (MI) on prognosis. METHODS: All patients admitted with first-time MI in 1997-2006 were included by use of individual-level linkage of nationwide registries. By claimed prescription of NSAIDs, availability of tablets was estimated within 14days prior to inclusion and defined ongoing use. Risk of death within 30days and risk of death or MI within 1year was analyzed by logistic regression and Cox proportional-hazard models, respectively. RESULTS: A total of 97,458 patients were included (mean age 69.9 [SD 13.2] years and 62% males); the 30day and 1year mortality rates were 18.1% and 27.7%, respectively. Ongoing NSAID treatment was identified in 12,156 (12.5%) patients and 30-day mortality was significantly increased in patients receiving rofecoxib (odds ratio [OR] 1.43; 95% confidence interval [CI] 1.22-1.68) and celecoxib (OR 1.23; CI 1.03-1.47) relative to no use of NSAIDs. Correspondingly, the 1-year rate of death or recurrent MI was significantly increased in patients receiving rofecoxib (hazard ratio [HR] 1.15; CI 1.04-1.27), celecoxib (HR 1.13; CI 1.01-1.26), diclofenac (HR 1.12; CI 1.04-1.20) or any NSAID use (HR 1.05; CI 1.02-1.09). No association was found for naproxen or ibuprofen. CONCLUSION: Ongoing treatment with NSAIDs and in particular the cyclooxygenase-2-selective inhibitors rofecoxib, celecoxib, and diclofenac is associated with worsened prognosis in patients admitted with first-time MI.

AB - BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with increased cardiovascular morbidity and mortality. The purpose of this study was to examine the effect of ongoing NSAID treatment at time of admission for myocardial infarction (MI) on prognosis. METHODS: All patients admitted with first-time MI in 1997-2006 were included by use of individual-level linkage of nationwide registries. By claimed prescription of NSAIDs, availability of tablets was estimated within 14days prior to inclusion and defined ongoing use. Risk of death within 30days and risk of death or MI within 1year was analyzed by logistic regression and Cox proportional-hazard models, respectively. RESULTS: A total of 97,458 patients were included (mean age 69.9 [SD 13.2] years and 62% males); the 30day and 1year mortality rates were 18.1% and 27.7%, respectively. Ongoing NSAID treatment was identified in 12,156 (12.5%) patients and 30-day mortality was significantly increased in patients receiving rofecoxib (odds ratio [OR] 1.43; 95% confidence interval [CI] 1.22-1.68) and celecoxib (OR 1.23; CI 1.03-1.47) relative to no use of NSAIDs. Correspondingly, the 1-year rate of death or recurrent MI was significantly increased in patients receiving rofecoxib (hazard ratio [HR] 1.15; CI 1.04-1.27), celecoxib (HR 1.13; CI 1.01-1.26), diclofenac (HR 1.12; CI 1.04-1.20) or any NSAID use (HR 1.05; CI 1.02-1.09). No association was found for naproxen or ibuprofen. CONCLUSION: Ongoing treatment with NSAIDs and in particular the cyclooxygenase-2-selective inhibitors rofecoxib, celecoxib, and diclofenac is associated with worsened prognosis in patients admitted with first-time MI.

U2 - 10.1016/j.ijcard.2012.10.004

DO - 10.1016/j.ijcard.2012.10.004

M3 - Journal article

C2 - 23117013

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -

ID: 48452874